Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma
Conditions: Central Nervous System B-Cell Non-Hodgkin Lymphoma; Recurrent Central Nervous System Lymphoma; Refractory Central Nervous System Lymphoma Interventions: Drug: Ibrutinib; Biological: Nivolumab Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials